4.7 Article

Genetic Regulation of Platelet Receptor Expression and Function Application in Clinical Practice and Drug Development

期刊

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.110.218131

关键词

gene expression; hemostasis; platelets; receptors; thrombosis

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
  3. Daiichi Sankyo, Inc.
  4. Lilly USA, LLC
  5. Merck Research Laboratories
  6. Regado Biosciences, Inc.
  7. Medicines Company
  8. Sanofi-Aventis
  9. Schering-Plough
  10. Daiichi/Eli Lilly
  11. Schering Corporation
  12. BMS/Sanofi Partnership
  13. Johnson Johnson
  14. Merck and Co
  15. Regado Biosciences

向作者/读者索取更多资源

Understanding genetic contributions to platelet function could have profound clinical ramifications for personalizing platelet-directed pharmacotherapy, by providing insight into the risks and possible benefits associated with specific genotypes. This article represents an integrated summary of presentations related to genetic regulation of platelet receptor expression and function given at the Fifth Annual Platelet Colloquium in January 2010. It is supplemented with additional highlights from the literature covering (1) approaches to determining and evidence for the associations of genetic variants with platelet hypo-and hyperresponsive phenotypes, (2) the ramifications of these polymorphisms with regard to clinical responses to antiplatelet therapies, and (3) the role of platelet function/genetic testing in guiding antiplatelet therapy. (Arterioscler Thromb Vasc Biol. 2010;30:2372-2384.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据